Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment | | |
Immunotherapy in biliary tract cancers: Current evidence and future perspectives | | 2022 |
Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function | | 2022 |
Dynamic Prediction of Survival After Curative Resection of Intrahepatic Cholangiocarcinoma: A Landmarking-Based Analysis | Annals of Surgical Oncology | |
Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses | Annals of Surgical Oncology | |
Evaluation of abnormal gallbladder imaging findings: Surgical management and pathologic correlations in early‐stage gallbladder cancer | Clinical Case Reports (discontinued) | 2022 |
The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment | Revista De Gastroenterología De México (English Edition) | 2022 |
Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma | Hepatology Research | |
The Increasing Role of CT-Guided Cryoablation for the Treatment of Liver Cancer: A Single-Center Report | Cancers | 2022 |
The Therapeutic Role of PNU-74654 in Hepatocellular Carcinoma May Involve Suppression of NF-κB Signaling | Medicina (Lithuania) | 2022 |
Proton Therapy in the Management of Hepatocellular Carcinoma | Cancers | 2022 |
PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies | Cancers | 2022 |
II Consenso mexicano de carcinoma hepatocelular. Parte II: tratamiento | Revista De Gastroenterología De México | 2022 |
Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma. | Cancers | 2022 |
In Reply to Nguyen et al. | Practical Radiation Oncology | 2022 |
Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis | Cancers | 2022 |
Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies. | Clinical Epidemiology | 2022 |
The Significance of Systemic Inflammation Markers in Intrahepatic Recurrence of Early-Stage Hepatocellular Carcinoma after Curative Treatment. | Cancers | 2022 |
Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. | Cancer | 2022 |
The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. | Journal of Gastrointestinal Cancer | 2022 |
Association of County-Level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment among Patients with Hepatocellular Carcinoma. | Annals of Surgical Oncology | 2022 |
Precision Medicine Targeting Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives. | Frontiers in Oncology | 2022 |
Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. | Frontiers in Oncology | 2022 |
ASO Author Reflections: Usage of Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma. | Annals of Surgical Oncology | 2022 |
Impact of the Cancer and Aging Research Group score and treatment intensity on survival and toxicity outcomes in older adults with advanced noncolorectal gastrointestinal cancers. | Cancer | 2022 |
Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma | Journal of Clinical and Translational Hepatology | 2022 |
Metabolism-Associated Gene Signatures for FDG Avidity on PET/CT and Prognostic Validation in Hepatocellular Carcinoma. | Frontiers in Oncology | 2022 |
Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature. | Frontiers in Oncology | 2022 |
Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time? | Hepatology | 2021 |
Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. | Journal of Personalized Medicine | 2021 |
Survival following liver transplantation for locally-advanced, unresectable intrahepatic cholangiocarcinoma | American Journal of Transplantation | 2021 |
Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study | Hepatology Communications | 2021 |
Focal neuroendocrine carcinoma mixed with adenocarcinoma of the gallbladder with aggressive lymph node metastasis in a patient who did not meet the mixed neuroendocrine-non-neuroendocrine neoplasm criteria | Clinical Journal of Gastroenterology | 2021 |
Surgical management of intrahepatic cholangiocarcinoma | Expert Review of Anticancer Therapy | 2021 |
External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline | Practical Radiation Oncology | 2021 |
Patterns of Recurrence and Its Effective Treatment | | 2020 |
Benign and Malignant Tumors of the Liver | | 2020 |
Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis | Cancers | 2021 |
Systemic therapy of hepatocellular carcinoma: reality and prospects | Annals of HPB Surgery | 2020 |
Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports | World Journal of Clinical Cases | 2020 |
Regional Therapies in Hepatocellular Carcinoma and Cholangiocarcinoma | | 2020 |
Second-line treatment of hepatocellular carcinoma: from theory to practical issues | Meditsinskiy Sovet | 2019 |
Screening for Gastrointestinal Cancers | | 2019 |
Gallbladder Cancer: Current and Emerging Therapies | | 2019 |
Transarterial Therapies | | 2019 |
Staging and Prognosis | | 2019 |
Hepatobiliary Malignancies | | 2018 |
Role of Radiation Therapy in Hepatocellular Carcinoma | | 2018 |
Liver | | |
Benign and Malignant Tumors of the Liver | | 2017 |